Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis

Fig. 2

League tables of treatments for PFS and adverse events. A PFS in the overall population with ovarian cancer, B PFS for women with BRCAm, C PFS for women with HRD, D Adverse events in all populations. Hazard ratio (HR) or relative risk (RR) of the upper left treatment (intervention) vs. lower right (comparator) was estimated. BRCAm, BRCA1/2 mutation; HRD, homologous recombination deficiency

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us